A myeloma bone marrow transplant — technically called an autologous stem cell transplant — is the closest thing we have to a standard-of-care intensive treatment for eligible multiple myeloma patients. It doesn’t cure myeloma in most cases, but it consistently extends remission. In landmark trials, patients who received a transplant after initial therapy had a median progression-free survival of roughly 50 months compared to about 36 months with chemotherapy alone. That’s a meaningful difference when you’re fighting an incurable blood cancer.
Here’s the reality: not every myeloma patient needs or qualifies for a transplant. But if you or someone you love has been diagnosed with multiple myeloma, the transplant conversation is going to come up — usually early. This guide covers who qualifies, exactly what happens during the procedure, what recovery looks like, and the honest data on outcomes.
What Exactly Is a Myeloma Bone Marrow Transplant?
Multiple myeloma is a cancer of plasma cells — the white blood cells responsible for making antibodies. These malignant cells accumulate in the bone marrow, crowding out healthy blood cell production and causing bone destruction, anemia, kidney damage, and immune dysfunction.
A bone marrow transplant for myeloma almost always means an autologous stem cell transplant (ASCT). Your own stem cells are collected before treatment, you receive high-dose chemotherapy (typically melphalan at 200 mg/m²) to wipe out as much myeloma as possible, and then your stored stem cells are infused back to rebuild your bone marrow. Think of it as a “rescue” — the transplant isn’t the treatment itself; it’s what allows you to survive the aggressive chemotherapy.
Allogeneic transplants (using a donor’s stem cells) are rarely used for myeloma today because of high treatment-related mortality rates — historically 15-25%. They’re reserved for clinical trials or very specific high-risk situations.
Autologous vs. Allogeneic: Key Differences
| Feature | Autologous (ASCT) | Allogeneic |
|---|---|---|
| Stem cell source | Patient’s own cells | Matched donor (sibling or unrelated) |
| Treatment-related mortality | 1-3% | 15-25% |
| Graft-vs-host disease risk | None | Significant |
| Graft-vs-myeloma effect | No | Yes — potential for deeper, lasting response |
| Frequency of use in myeloma | Standard of care for eligible patients | Rare; mostly clinical trials |
| Median progression-free survival | ~40-50 months | Variable; data limited |
Who Qualifies for a Myeloma Transplant?
Transplant eligibility depends more on your overall fitness than your age, though most guidelines use age 65-70 as a general cutoff. The key factors oncologists assess include:
- Age: Typically under 65-70, though fit patients in their early 70s may still qualify
- Performance status: ECOG score of 0-2 (meaning you can care for yourself and are active most of the day)
- Organ function: Adequate heart, lung, liver, and kidney function — cardiac ejection fraction generally needs to be above 40%, and pulmonary function tests (DLCO) above 50% predicted
- Disease status: Ideally at least a partial response to initial (induction) chemotherapy
Patients with severe comorbidities — uncontrolled diabetes, advanced heart failure, significant lung disease — are typically steered toward non-transplant regimens, which have improved dramatically in recent years.
The Transplant Process: Step by Step
1. Induction Therapy (3-6 Cycles)
Before transplant, you’ll receive 3-6 cycles of combination chemotherapy. The most common current regimen is VRd — bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone. The goal is to reduce tumor burden as much as possible before the transplant.
2. Stem Cell Collection (Apheresis)
You’ll receive growth factor injections (G-CSF, sometimes with plerixafor) for several days to mobilize stem cells from your bone marrow into your bloodstream. Blood is then drawn through an IV line and run through a machine that separates out stem cells. This typically takes 1-2 sessions, each lasting 4-6 hours. The minimum target is usually 2 million CD34+ cells per kilogram of body weight — most centers aim for 4-6 million to bank enough for a potential second transplant.
3. Conditioning (High-Dose Chemotherapy)
You’ll receive a single high dose of melphalan (200 mg/m², or 140 mg/m² for patients with reduced kidney function). This is the most intensive part — it obliterates the remaining myeloma cells along with your healthy marrow. Side effects are significant: severe nausea, mouth sores (mucositis), diarrhea, and complete bone marrow suppression.
4. Stem Cell Infusion (Day 0)
Two days after melphalan, your frozen stem cells are thawed and infused through your central line — it looks a lot like a blood transfusion. The actual infusion takes about 30 minutes. Some patients notice a garlic-like taste or smell from the DMSO preservative.
5. Engraftment and Recovery
Engraftment — when your new marrow starts producing blood cells again — usually happens between days 10 and 14. You’ll be severely immunocompromised during this window. Most patients spend 2-3 weeks in the hospital, and full recovery takes 2-3 months. Fatigue often lingers for 6 months or more.
Survival and Outcomes: The Honest Numbers
Transplant-eligible myeloma patients treated with modern induction therapy plus ASCT have a median overall survival exceeding 6-7 years, with some studies reporting medians approaching 8-10 years depending on risk profile. The DETERMINATION trial (2022) confirmed that adding transplant to VRd improved median progression-free survival from 46 months to 68 months.
However, outcomes vary enormously based on cytogenetic risk:
- Standard risk (e.g., t(11;14), trisomies): Median overall survival 8-10+ years
- High risk (e.g., del(17p), t(4;14), gain(1q)): Median overall survival 4-5 years even with transplant
- Double/triple hit (2+ high-risk features): Poorer prognosis; transplant benefit is debated
Relapse after transplant is expected for most patients. The question isn’t usually if myeloma comes back — it’s when. Maintenance therapy with lenalidomide after transplant has been shown to extend progression-free survival by roughly 2 years and improve overall survival.
Is Transplant Still Worth It in 2024?
This is the question hematologists are actively debating. New therapies — CAR-T cell therapy (e.g., ciltacabtagene autoleucel), bispecific antibodies (e.g., teclistamab), and quadruplet induction regimens adding anti-CD38 antibodies like daratumumab — are producing unprecedented response rates. Some experts believe transplant may eventually become unnecessary for certain patients.
For now, ASCT remains the standard for transplant-eligible patients based on available phase 3 data. But clinical trials like GRIFFIN and PERSEUS are testing whether adding daratumumab to VRd plus transplant can push outcomes even further. Ask your oncologist about applicable trials.
Frequently Asked Questions
Can a bone marrow transplant cure multiple myeloma?
In the vast majority of cases, no. ASCT extends remission and improves survival, but myeloma almost always returns eventually. A small percentage of patients — possibly 10-15% — achieve very long remissions (10+ years) that may be functionally close to a cure, particularly those with standard-risk cytogenetics who achieve MRD-negative status.
How long is the hospital stay for a myeloma transplant?
Most patients spend 14-21 days in the hospital. Some centers now offer outpatient transplants for carefully selected patients who live close to the treatment center and have a reliable caregiver at home.
What’s the mortality rate of the transplant itself?
Treatment-related mortality for autologous transplant in myeloma is low — approximately 1-3% at experienced centers. The most common serious complications are infections during the neutropenic period and organ toxicity from melphalan.
Should I get a second (tandem) transplant?
Tandem transplants — two ASCTs performed 2-6 months apart — benefit a specific group: patients who don’t achieve at least a very good partial response (VGPR) after their first transplant, and possibly high-risk patients. For patients who achieve VGPR or better after transplant #1, a second transplant generally doesn’t add significant benefit. The StaMINA trial helped clarify this.
What happens if myeloma returns after transplant?
Relapse is treated with different drug combinations than what you received initially. Options include carfilzomib-based regimens, pomalidomide combinations, monoclonal antibodies (daratumumab, elotuzumab), CAR-T therapy, or a second autologous transplant if relapse occurs more than 18-24 months after the first. Your options are broader than ever.
When to Talk to Your Doctor
If you’ve been diagnosed with multiple myeloma, bring up the transplant conversation early — ideally at diagnosis. Even if you’re not sure you want a transplant, collecting and banking stem cells before prolonged chemotherapy is wise because some drugs (especially lenalidomide) can impair stem cell mobilization over time.
Specifically, ask your hematologist:
- What is my cytogenetic risk profile, and how does it affect transplant benefit?
- Am I a candidate for ASCT based on my fitness and organ function?
- Should we collect stem cells early even if we defer transplant?
- Are there clinical trials comparing transplant to newer therapies that I might qualify for?
- What’s the plan for maintenance therapy after transplant?
Getting a second opinion at an academic myeloma center — especially if you have high-risk disease — is never a bad idea. Myeloma is a rapidly evolving field, and specialists who see hundreds of patients per year may offer treatment approaches that community oncologists don’t have access to.
